|
The company received permission in form CT-20 to import for sale and distribution of Tremelimumab (Imjudo).
Through this approval, Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC).
The receipt of this permission paves way for the launch of Tremelimumab (Imjudo) solution of 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations in single dose vials) in India for the specified indication, subject to the receipt of related statutory approvals.
Astrazeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company.
Astrazeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company.
The company's standalone net profit declined 38.3% to Rs 17.27 crore in Q4 FY23 as compared with Rs 27.98 crore in Q4 FY22. Net sales jumped 22.7% year on year to Rs 284.70 crore in Q4 FY23.
|